Abstract
SARS-CoV-2 transmission is largely driven by heterogeneous dynamics at a local scale, leaving local health departments to design interventions with limited information. We analyzed SARS-CoV-2 genomes sampled between February 2020 and March 2022 jointly with epidemiological and cell phone mobility data to investigate fine scale spatiotemporal SARS-CoV-2 transmission dynamics in King County, Washington, a diverse, metropolitan US county. We applied an approximate structured coalescent approach to model transmission within and between North King County and South King County alongside the rate of outside introductions into the county. Our phylodynamic analyses reveal that following stay-at-home orders, the epidemic trajectories of North and South King County began to diverge. We find that South King County consistently had more reported and estimated cases, COVID-19 hospitalizations, and longer persistence of local viral transmission when compared to North King County, where viral importations from outside drove a larger proportion of new cases. Using mobility and demographic data, we also find that South King County experienced a more modest and less sustained reduction in mobility following stay-at-home orders than North King County, while also bearing more socioeconomic inequities that might contribute to a disproportionate burden of SARS-CoV-2 transmission. Overall, our findings suggest a role for local-scale phylodynamics in understanding the heterogeneous transmission landscape.
Author Summary State- or county-level data collected as part of routine surveillance often mask significant local differences in SARS-CoV-2 transmission due to their lack of granularity. This leaves local public health departments with incomplete information for resource allocation. Using King County, Washington as an example of a diverse, metropolitan US county, we leveraged genomic epidemiology to understand differences in transmission between North and South King County, two adjacent regions within the same county with stark socioeconomic differences. By combining epidemiological, mobility, and demographic data, we found that these two regions had divergent SARS-CoV-2 epidemic trajectories following the start of statewide stay-at-home orders in March 2020. Our approach also revealed important differences in the role of viral importations and persistence of local viral transmission on changing SARS-CoV-2 incidence in the background of large-scale non-pharmaceutical interventions. Our work shows that we can use genomic epidemiology to reveal differences in transmission at a local scale, which can inform equitable resource allocation at a local level to reduce the burden of infectious diseases.
Competing Interest Statement
ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead and Merck, outside of the described work. HC reports consulting with Ellume, Pfizer, the Bill & Melinda Gates Foundation, Glaxo Smith Kline, and Merck. She has received research funding from Emergent Ventures, Gates Ventures, Sanofi Pasteur, the Bill & Melinda Gates Foundation, and support and reagents from Ellume and Cepheid outside of the submitted work. All other authors declare no competing interests.
Funding Statement
MIP is an ARCS Foundation scholar. T.B. is a Howard Hughes Medical Institute Investigator. This work is supported by NIH NIGMS R35 GM119774 and HHMI COVID-19 Collaboration Initiative award to T.B. L.H.M. is funded by NIH grant number 4R00AI147029-04. A.C.P. is funded by Gates Ventures. Sequencing of specimens by the Brotman Baty Institute of Precision Medicine was funded by Gates Ventures (Seattle Flu Study award), Howard Hughes Medical Institute (HHMI COVID-19 Collaboration Initiative award) and the CDC (contract number 200-2021-10982). Sequencing of specimens by UW Virology was funded by Fast Grants (award #2244), the CDC (contracts 75D30121C10540 and 75D30122C13720) and WADOH (contract HED26002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Washington State Institutional Review Board designated this study as exempt. Sequencing and analysis of samples from the Seattle Flu Study was approved by the Institutional Review Board (IRB) at the University of Washington (protocol STUDY00006181). Sequencing of remnant clinical specimens at UW Virology Lab was approved by the University of Washington Institutional Review Board (protocol STUDY00000408).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors jointly supervised this work.
Added new supplemental figures and changed main figure order to allow for better clarity
Data Availability
Nextstrain builds, BEAST XMLS, scripts, sequence information, and de-identified data can be found at https://github.com/blab/ncov-king-county. All sequences are available on GenBank and GISAID with accession numbers found in the supplementary information.
